Literature DB >> 15083850

Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.

Liliana Gazzuola Rocca1, Barbara P Yawn, Peter Wollan, W Ray Kim.   

Abstract

BACKGROUND: Chronic hepatitis C, a treatable condition caused by the hepatitis C virus (HCV), can be found in almost all primary care and community practices. The rate of hepatitis C treatment is low, however. This study explores the frequency of hepatitis C treatment, documented discussions of treatment consideration, and the reasons treatment may not be offered in a community population.
METHODS: This study is a retrospective medical record review of care provided to all patients in Olmsted County, Minn, who had a confirmed diagnosis of hepatitis C. Using all records from all health care providers in Olmsted County, the rates of documented discussions regarding hepatitis C treatment and the treatment rates by specialty of diagnosing physician were assessed. In addition, comorbidities listed as reasons not to treat and or comorbid conditions in patients without a documented treatment discussion were assessed.
RESULTS: Of the 366 patients with hepatitis C, 62% were men. Hepatitis C was more commonly diagnosed by generalist physicians (41% of cases). Treatment discussions were documented for 77% of patients with hepatitis C diagnosed by either a generalist or a gastrointestinal specialist (gastroenterologist or hepatologist) compared with 46% of patients with hepatitis C diagnosed by other physicians. Generalists' patients were more likely to have documented contraindications to treatment and were only one half as likely to receive hepatitis C treatment compared with patients with hepatitis C diagnosed by gastrointestinal specialists (16% vs 33%). Documented attempts to treat or reassess after resolution of potentially reversible contraindications to hepatitis C therapy were infrequent.
CONCLUSIONS: In this community population, hepatitis C treatment was discussed with the majority of patients with a diagnosis of hepatitis C; however, the actual treatment rate was low. Many opportunities exist for treating more patients for HCV infection, particularly those found during emergency care and chemical dependency treatment. In addition, generalists' recognition and treatment of potentially reversible contraindications to hepatitis C therapy could greatly increase the number of treatment candidates.

Entities:  

Mesh:

Year:  2004        PMID: 15083850      PMCID: PMC1466643          DOI: 10.1370/afm.62

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  28 in total

1.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

2.  The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.

Authors:  G L Armstrong; M J Alter; G M McQuillan; H S Margolis
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

Review 4.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

5.  Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.

Authors:  T Poynard; J McHutchison; Z Goodman; M H Ling; J Albrecht
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

6.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

7.  Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Authors:  H Tanaka; H Tsukuma; A Kasahara; N Hayashi; H Yoshihara; M Masuzawa; T Kanda; T Kashiwagi; A Inoue; M Kato; A Oshima; Y Kinoshita; T Kamada
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

8.  Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

Authors:  J B Wong; W G Bennett; R S Koff; S G Pauker
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

9.  Quantitation of hepatitis C virus RNA in liver transplant recipients.

Authors:  O Chazouilleres; M Kim; C Combs; L Ferrell; P Bacchetti; J Roberts; N L Ascher; P Neuwald; J Wilber; M Urdea
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

10.  A longitudinal analysis of hepatitis C virus replication following liver transplantation.

Authors:  E J Gane; N V Naoumov; K P Qian; M U Mondelli; G Maertens; B C Portmann; J Y Lau; R Williams
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

View more
  19 in total

1.  The future of family medicine? Reflections from the front lines reveal frustration and opportunity.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

2.  Rate, delay and predictors of hepatitis C treatment in British Columbia.

Authors:  Alan Hoi Lun Yau; Terry Lee; Alnoor Ramji; Hin Hin Ko
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

Review 3.  Demographics of hepatitis C virus today.

Authors:  Stevan A Gonzalez; Gary L Davis
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-03-06

Review 4.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

5.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

6.  Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California.

Authors:  Lorenzo Rossaro; Cara Torruellas; Sandeep Dhaliwal; Jacqueline Botros; Guiselle Clark; Chin-Shang Li; Mia M Minoletti
Journal:  Dig Dis Sci       Date:  2013-10-24       Impact factor: 3.199

7.  Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population.

Authors:  L Kakinami; R C Block; M J Adams; S E Cohn; B Maliakkal; S G Fisher
Journal:  Int J Clin Pract       Date:  2013-01       Impact factor: 2.503

8.  Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

Authors:  J Grebely; K Petoumenos; G V Matthews; P Haber; P Marks; A R Lloyd; J M Kaldor; G J Dore; M Hellard
Journal:  Drug Alcohol Depend       Date:  2010-03-01       Impact factor: 4.492

9.  Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

Authors:  Maciej Witkos; Qi-Long Yi; Jenny Heathcote; Moira K Kapral; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

10.  Context of clinical care: the case of hepatitis C in underserved communities--a report from the Primary Care Multiethnic Network (PRIME Net) Consortium.

Authors:  Robert R Leverence; Robert L Williams; Wilson Pace; Bennett Parnes; Yvonne Fry-Johnson; Dorothy R Pathak; Betty Skipper; Elvan Daniels; Philip Kroth
Journal:  J Am Board Fam Med       Date:  2009 Nov-Dec       Impact factor: 2.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.